 1. Characterize the population pharmacokinetics of rifapentine and 25-desacetyl rifapentine, using sparse PK data from Study 31 and intensive PK data from Study 31 PKPD. Using the population PK model, determine post-hoc Bayesian estimates of individual-level PK parameters. 